NewAmsterdam Pharma (NAMS) Operating Income (2023 - 2026)
NewAmsterdam Pharma (NAMS) reported Operating Income of -$58.4 million for Q1 2026, up 15.24% on a YoY basis from -$50.7 million in Q1 2025, and up 11.46% sequentially from -$66.0 million in Q4 2025.
NewAmsterdam Pharma (NAMS) Operating Income (2023 - 2026) Analysis & Trends
NewAmsterdam Pharma (NAMS) has 4 years of Operating Income data on file, last reported at -$58.4 million in Q1 2026.
- For the quarter ending Q1 2026, Operating Income rose 15.24% year-over-year to -$58.4 million; the trailing twelve-month figure through Mar 2026 stood at -$215.2 million (down 13.41% YoY), and the FY2025 full-year result was -$225.7 million, down 28.02% from the prior year.
- Operating Income advanced to -$58.4 million in Q1 2026, from -$66.0 million in the prior quarter.
- In the past five years, Operating Income ranged from a high of -$25.0 million in Q3 2024 to a low of -$68.9 million in Q1 2025.
- A 4-year average of -$49.5 million and a median of -$51.1 million in 2023 frame the typical range for Operating Income.
- Across the five-year window, Operating Income jumped 49.55% in 2024 and tumbled 120.55% in 2025, its largest moves.
- Tracing NAMS's Operating Income over 4 years: stood at -$51.1 million in 2023, then increased by 15.36% to -$43.2 million in 2024, then slumped by 52.63% to -$66.0 million in 2025, then rose by 11.46% to -$58.4 million in 2026.
- Business Quant data shows NAMS's Operating Income at -$58.4 million in Q1 2026, -$66.0 million in Q4 2025, and -$55.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,072.09 Bn | 67,072.09 Bn | - | -27.75 Mn |
| 2 | Nanobiotix | 1,894.61 Bn | 1,894.55 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.76 Mn |
| 4 | BeOne Medicines | 471.64 Bn | 466.85 Bn | 1.35 Bn | 249.90 Mn |
| 5 | Vertex Pharmaceuticals | 121.72 Bn | 114.47 Bn | 2.59 Bn | 1.14 Bn |
| 6 | Regeneron Pharmaceuticals | 68.28 Bn | 59.52 Bn | 3.31 Bn | 642.90 Mn |
| 7 | Belite Bio | 61.40 Bn | 61.40 Bn | - | -32.68 Mn |
| 8 | Argenx Se | 56.94 Bn | 56.94 Bn | 1.18 Bn | 394.00 Mn |
| 9 | Revolution Medicines | 37.37 Bn | 37.37 Bn | - | -445.22 Mn |
| 10 | NewAmsterdam Pharma | 3.64 Bn | 3.64 Bn | - | -58.42 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -58.42 Mn |
| Dec 31, 2025 | -65.98 Mn |
| Sep 30, 2025 | -55.14 Mn |
| Jun 30, 2025 | -35.64 Mn |
| Mar 31, 2025 | -68.93 Mn |
| Dec 31, 2024 | -43.23 Mn |
| Sep 30, 2024 | -25.00 Mn |
| Jun 30, 2024 | -52.58 Mn |
| Mar 31, 2024 | -55.48 Mn |
| Dec 31, 2023 | -51.07 Mn |
| Sep 30, 2023 | -49.56 Mn |
| Jun 30, 2023 | -42.48 Mn |
| Mar 31, 2023 | -39.85 Mn |